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ABSTRACT 
Background: Total Mesorectal Excision (TME) is widely accepted as the standard surgical 
treatment for mid and low rectal cancer. The robotic (RoTME) and laparoscopic (LaTME) 
approaches to treat rectal cancer are shown to be feasible. Transanal TME (TaTME) is the most 
recent minimal invasive approach with promising results. We aimed to review the peri and 
postoperative complications associated with the three approaches.  
Methods: A systematic search in the PubMed and Embase databases was performed. Both 
authors assessed the studies for eligibility. Clinical randomized as well as non-randomized 
studies published during the last six years were included.  
Results: In total 39 studies (8094 patients) met the inclusion criteria. The LaTME had low rates 
of urinary complications, high rates of wound infection and intraabdominal abscesses. The 
RoTME had high rates of anastomotic leakages, but low rates of several other complications 
like; ureter and bladder injuries, bleeding and thirty-day mortality. The anastomosis performed 
more efficiently after TaTME with lower rates of anastomotic leakages, but higher rates of 
bleeding and 30-days mortality.  
Conclusions: The procedures each performed well in relation to the different complications 
however further research especially concerning TaTME and RoTME is needed. Focus on 
which procedure who best treats a specific tumor stage, tumor location and type of patient 
could possibly reduce complications and postoperative mortality in the future.  
 
Keywords: rectal cancer; complications; total mesorectal excision; transanal; robot-assisted 
surgery; laparoscopic surgery 
 
 
INTRODUCTION 
Rectal cancer is the fifth most common type of cancer in Denmark and less than 2 out of 3 will 
survive more than 5 years after diagnosis (1). Significant advances have been achieved in the 
treatment of rectal cancer over the past three decades. The introduction of TME (2), and 
improved preoperative diagnostic work-up have improved the short- and long-term results (3, 
4). TME is widely accepted as the standard surgical treatment for mid and low rectal cancer (3-
5).  
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It is general acknowledged that the laparoscopic approach for the treatment of rectal cancer has 
more advantages than open surgery with faster recovery, shorter hospital stays, decreased blood 
loss, infection rates and multi-organ failure as well as comparable long-term outcomes (6-11). 
However, LaTME is a technically difficult procedure in obese patients, males and patients with 
a narrow pelvis (12, 13).  
RoTME is a feasible approach with potential advantages compared with laparoscopy and open 
surgery (14-17), and is reported to be equivalent to laparoscopic surgery with respect to the 
short-term perioperative and oncologic outcomes (15, 18, 19). However, the true cost-benefit 
advantages still are questionable (12, 20, 21), and results of a randomized trial are awaited (22). 
As the newest approach, TaTME shows promising results as a safe and effective technique with 
acceptable short-term outcomes (23, 24).  
Perioperative complications play an important role in the adoption of the appropriate approach, 
like both the pathological outcomes and the complication rates do. The aim of this review is to 
highlight common and severe reported complications associated with LaTME, RoTME and 
TaTME. 
 
MATERIALS AND METHODS 
A systematic search was conducted in PubMed and Embase databases on October 7 2016 using 
the following words separately and in combination: “complication”, “surgery”, “rectal”, 
“cancer”, “total mesorectal excision”, “transanal”, “TaTME”, “laparoscopic” and “robotic”. 
Only full text articles in English were included. The search and the review processes were 
undertaken by the two authors using the PRISMA guidelines (25). The search identified 147 
clinical trials. After crosschecking the reference lists 24 additional articles were retrieved. After 
removing duplicates 133 articles remained and abstracts were read systematically for eligibility. 
Only articles published during the last six years were included, as all these three approaches 
have been practiced during this period. All prospective and retrospective randomized and non-
randomized studies concerning TME were included. Articles not sufficiently specifying data 
about complications and studies combining the procedure with other surgical techniques were 
excluded. We focused on the following intraoperative and postoperative complications; 
bleeding, estimated blood loss (EBL), need for blood transfusion, anastomose leakage, urine 
retention and complication, bladder and urethral injury, urinary tract infection, wound infection, 
bowel injury, intraabdominal and pelvic abscess and 30-days mortality.  
In total, we included 39 studies corresponding to 8094 patients. See the PRISMA flow diagram 
for detail (Figure 1). 
 
RESULTS 
The included studies were single center as well as multicenter clinical studies, prospective or 
retrospective, including several randomized studies. Numerous studies were comparative or 
case-matched studies, where data originally were compared with open surgery (7-10, 13, 26-
30). In six studies, LaTME was compared with RoTME (12, 15, 31-34) while four studies 
compared LaTME and TaTME (5, 35-37). The rest focused on a single procedure.  
The extracted data are presented systematically in Table 1. 
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Indications 
The pathology was cancer in all studies except Penna et al (23), who included 86 (out of 720) 
benign cases. All cancer stages were included though Yamamoto et al (38) and Fuji et al (39) 
only included stage Tis-T2 tumors, Fleshman et al (29) included T2-T3 and Baik et al (28) 
included T1-T3. Rouanet et al (40) selected men with narrow pelvis, fatty mesorectum, high 
BMI, large prostate and presence of fibrosis. Neither if the operation had to be converted into 
open surgery nor the experience of the surgeon effected if a study was included or not.  
Five studies (7, 31, 35, 41, 42) only reported patients treated with neoadjuvant therapy while 
several studies (28, 29, 36, 43) included both cases with and without neoadjuvant treatment. 
 
Peri and postoperative data 
Bleeding and estimated blood loss (EBL) 
Fernandez-Hevia et al (37) reported one readmission in the LaTME group because of 
hemorrhage, while Cho et al (12) reported two conversions to open surgery in the LaTME group 
due to intractable major vessel bleeding. Van der Pas et al (9) reported conversion in six out of 
22 cases because of bleeding. Hellan et al (16) reported three cases of bleeding after RoTME. 
Chen et al (35) subdivided bleeding into presacral bleedings and other bleedings. Another two 
studies subdivided as intraabdominal or anastomotic bleeding (24, 38).  
Two studies found no significant difference in EBL between TaTME and LaTME (35, 36) and 
three studies found no significant difference between RoTME and LaTME in bleeding or EBL 
(31, 32, 44). Perdawood (5) reported a lower blood loss for TaTME than LaTME. Penna et al 
(23) reported an intraoperative blood loss during TaTME of less than 100ml in 61% of the 
cases, and furthermore reported six cases (1%) of bleeding more than one liter. Serra-Aracil et 
al (45) reported 158 ml in EBL after TaTME, and proclaimed it lower than the laparoscopic 
group of the COLOR II trail. Ielpo et al (33) reported the highest EBL = 280 ml for RoTME 
(range 0-4000ml) while Park et al (34) reported the lowest EBL = 77.6 ml (range 0-700 ml). 
Two LaTME studies (38, 39) reported EBL of 28 ml and 20 ml respectively.  
Overall, 2.9% of the patients had perioperative bleeding during TaTME and a general average 
EBL at 107.9 ml for every case. 1.1% of the patients had perioperative bleeding during RoTME 
and an average EBL at 143.7 ml. The LaTME studies reported 1.4% of patients with bleeding 
and an average EBL at 115.1 ml. See Table 2 for calculations of the percentage and an 
overview. 
 
Need for blood transfusion 
Approximately 20% required blood transfusion after TaTME in Rouanet et al (40). Lacy et al 
(24) reported three blood transfusions because of anemia and one due to hemorrhage after 
TaTME. Another study (38) reported 1,6 % of cases requiring blood transfusion after LaTME.  
Overall, 5% of patients undergoing TaTME, 2% of patients after RoTME and 2.3% after 
LaTME had peri or postoperative blood transfusion. 
 
Anastomotic leakage 
Five studies reported the diagnosis as a clinical suspicion where different criteria were reported; 
fever and pain, pus, gas or fecal discharge from the drain, pelvic abscess and peritonitis (9, 10, 
31, 33, 46). After TaTME, Penna et al (23) reported 32 cases identified early and eight cases 
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identified after 30 days. Perdawood (5) reported four patients readmitted after TaTME and one 
after LaTME because of anastomotic leakage. Penninckx et al (26) subdivided leakage as: 
minor (14 cases) and major (30 cases) leaks after LaTME. Schiphorst et al (30) reported four 
out of 46 cases leading to reoperation or fistula as Hu et al (7) reported 3.1% of leakage and 
concluded that LaTME after neoadjuvant CRT is a safe procedure. Cho et al (12) reported no 
early postoperative difference between LaTME vs RoTME while Chen et al (47) reported no 
statistically significant difference in leakage rates between the TaTME and LaTME groups. As 
for postoperative pelvic abscess formation. 
Overall 5.8% of the patients after TaTME, 8.0% after RoTME and 6.9% after LaTME had 
anastomotic leakage.  
 
Urine retention and complications 
Kang et al (48) defined voiding difficulty as urinary retention or urinary incontinence requiring 
urological medication or reinsertion of a Foley catheter. Tuech et al (46) reported five patients 
(8.9%) with postoperative urinary retention, all treated by temporary urethral catheterization. 
After three months, all patients reported normal urinary function. Kang et al (49) reported two 
urinary retentions during TaTME and one (47) reported three cases of urinary retention after 
removing the Foley catheter after LaTME and none after TaTME. Five cases of neurogenic 
urinary retention were reported after LaTME in one study (38). 
In summary, 4.7% after TaTME, 4.9% after RoTME and 2.5% after LaTME had urinary 
retention or complications.  
 
Bladder and urethral injury 
Penna et al (23) reported five cases of urethral injuries (0.7%) and two bladder injuries (0.3%) 
during perineal dissection after TaTME while Kang et al (49) reported one urethral injury as a 
result of dissecting too anteriorly into an enlarged prostate. Rasulov et al (43) reported one 
bladder injury during TaTME, which was closed laparoscopically and the patient was 
discharged with a urinary catheter, removed one week later. Park et al (34) reported one case 
of bladder injury because of tumor adhesion to the bladder as well responsible for conversion 
from RoTME to LaTME. One study (16) reported five genitourinary injuries after RoTME as 
just one out of two RoTME studies mentioning ureter or bladder injuries. Gong et al (13) 
reported one conversation from LaTME to open surgery due to ureteric injury. 
Overall, five bladder injuries and seven urethral injuries (1.5%) among 806 patients after 
TaTME were reported. 1.1% of the patients undergoing RoTME and 1.1% of the patients 
undergoing LaTME had intraoperative urethral or bladder injuries. 
 
Urinary tract infection 
Chen et al (35) reported as only TaTME-study one case among 50 patients and Levic et al (17) 
as the only RoTME-study none cases of urinary infection among 52 patients. Baik et al (28) 
reported two cases of grade three and one case of grade two urinary tract infection after LaTME. 
Concerning LaTME, 2.3% among 2814 patients suffered from postoperative urinary tract 
infection.  
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Wound infection 
Several studies (37, 42, 50, 51) emphasized that the TaTME procedure frequently allows 
specimen exteriorization without an abdominal incision, eliminating abdominal site morbidity 
as wound infection and hernia during specimen extraction. Yamamoto et al (38) reported that 
wound infections was diagnosed within 30 days of the operation according to the criteria of the 
Centers for Disease Control and Prevention. 
1.6% of the patients after TaTME, 1.9% after RoTME and 5.1% after LaTME suffered from 
wound infection.  
 
Bowel injury 
Perdawood (5) reported none bowel injury after TaTME. Two studies (12, 16) reported eight 
cases (1.1%) after RoTME, besides accentuated one patient that required conversation from 
RoTME to LaTME because of bowel perforation. Three studies (5, 9, 12) reported 0.8% of 
patients among 1002 patients after LaTME. 
 
Intraabdominal abscess 
Fifteen cases of pelvic or abdominal abscess without evidence of anastomotic leakage were 
reported by Penna et al (23), listed under intraabdominal abscess in our tables. Van der Pas (9) 
reported just abscess, listed as intraabdominal. Saklani et al (31) categorized intraabdominal 
abscess as a severe complication together with anastomotic leakage. Two studies (32, 34) 
reported no significant difference between RoTME and LaTME.  
Overall 2.3% of patients after TaTME, 1.4% after RoTME and 4.3% after LaTME had 
intraabdominal abscesses.  
 
Pelvic abscess 
Chen et al (35) reported three cases of pelvic abscess (8%) in the TaTME group and four cases 
(6%) in the LaTME group, all treated with antibiotics. Burke et al (42) reported four cases 
among 50 patients and two readmissions because of pelvic collection after TaTME. All leaks 
and pelvic collections were managed conservatively with antibiotics and prolonged drainage 
by Leong et al (52). Baik et al (28) graded it as a serious condition since one patient was 
hospitalized for 167 days because of pelvic abscess. Kang et al (48) reported no significant 
difference neither RoTME nor LaTME groups regarding pelvic abscess. 
Overall, 9.2% of the patients after TaTME, 1.9% after RoTME and 3.1% after LaTME had 
pelvic abscess. 
 
30-days mortality 
TaTME: Four studies (36, 42, 43, 51) concluded no postoperative mortality and two studies 
(36, 50) reported no surgery-associated deaths. Penna et al (23) reported 0.5% 30-days mortality 
and concluded to be similar according to previous rectal surgery trials. Muratore et al (53) 
reported a patient that died of myocardial infarction three days after surgery. Three studies (5, 
35, 37) did not mention mortality while Serra-Aracil (45) reported no 30-days mortality but a 
six percent median score on the CROPOSSUM scale. Overall, 2.1% patients died during the 
first 30 days after surgery. 
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RoTME: Two studies (34, 44) reported none cases of postoperative death without mentioning 
the follow-up period, while ten studies reported no cases in a follow-up period between 30 days 
and 3 years. Overall, one patient among 1414 (0.1%) died within the first 30 days. 
LaTME: Van der Pas (9) reported eight cases of death within 28 days. Penninckx et al (26) 
reported 11 cases among 764 patients (1,44%) while Yamamoto et al (38) reported the lowest 
mortality; none cases among 490. Overall 0.8% of the patients died during the first month after 
surgery. 
 
DISCUSSION 
Complications and mortality due to surgery are of major importance and widespread adoption 
of new surgical methods depends among other things on complication rates and risk of 
postoperative death. Consequently, the studies management of data is important. One source of 
potential reporting bias is the retrospective nature of twelve studies in this review. Here the 
choice of outcomes reported can be influenced by the results, potentially making published 
results misleading (54). Performance bias due to the experience among surgeons is another 
limiting factor as well as the number of surgeons performing the procedures vary from one (13) 
to 65 different surgeons (29). Several studies (12, 23, 24, 29, 32, 33, 43, 49, 55) reported 
complications using the Clavien-Dindo classification, which impeded the use of data in relation 
to our study design.  
Different diagnostic criteria and treatment options for the anastomotic leakage have been used 
throughout the studies (9, 10, 31, 33, 46). However, more cases of leakage in the RoTME group 
compared to the TaTME and LaTME were reported. The anastomosis seemed to perform more 
efficiently after TaTME with lower number of leaks. The seriousness of the cases was however 
unclear. Unfortunately, only readmission or not after anastomotic leakage have been reported, 
while the length of hospitalization and death has not (5, 23, 30, 42). The LaTME-group 
advanced with well experienced surgeons because of the longer use of laparoscopic approach 
(56), though no superior data found as compared with TaTME. Opposite, the LaTME 
performed better in relation to urine retention than RoTME and TaTME. Urine retention is a 
complication due to the operative procedure with iatrogenic injuries on the autonomic nerve in 
the narrow pelvic area (49), as well as the epidural analgesia which often is used during 
abdominal surgery (57). Nevertheless, patients mostly recovered and gained previously bladder 
function during weeks after surgery and hospitalization (46), and it was further more deemed 
to constitute a mild complication (31). 
Regarding wound infection, LaTME constituted a higher risk of post-operative wound 
infection, while TaTME possibly advantage from the fact that the specimen extraction were 
done transanal reducing intraabdominal wound related complications (37, 42, 50, 51).  
An almost equal percentage of urethral injuries among the three approaches were noted, as well 
as no higher percentage of injuries on nearby organs like bowel and bladder. Nevertheless, 
previous studies (58) reported the TaTME procedure to cause more cases of urethral injuries. 
Like injuries on organs, pelvic and intraabdominal abscess is a severe complication, which can 
lead to reoperation (23, 37, 42). The reported cases in the TaTME varied from 2.4% to 20% 
(23, 35, 59) what clearly underline the need for further research including big randomized trials. 
As well the indication for blood transfusion varied among the studies, well-illustrated by Liang 
et al (8) who transfused four patients out of 169 while Schiphorst et al (30) transfused ten out 
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of 86. The need for blood transfusion generally followed the bleedings and blood loss, but 
uniformed international evidence-based guidelines according to indication for blood 
transfusion might reduce bias.  
More bleeding and need for blood transfusion were reported among TaTME and presents a 
potential serious condition, with a need for acute conversion to open surgery (9, 12, 37). We 
calculated an average EBL for each one of the approaches, which possible distorted the 
accuracy, though gave us an opportunity to make a comparison. The average EBL was higher 
among RoTME than TaTME and LaTME. Baik et al (14) pointed, that prompt open conversion 
is impossible during RoTME because removing the robotic system is a time-consuming 
procedure, which is sometimes necessary for immediate control of serious bleeding. A fact that 
possible influence a higher blood loss during especially the most difficult RoTME operations 
ending up with conversion. 
The TaTME had a higher 30-days mortality rate than RoTME and LaTME, with poor evidence 
concerning cause of death. A recently published TaTME-study concluded no higher mortality 
according to previous rectal surgery trials (23). However, research with longer follow-up period 
is needed since TaTME is a new technique meaning that surgeons improved in the studies (5, 
23, 36, 49) and possibly reduced the complication rate in step with gaining higher level of 
experience. 
 
CONCLUSION 
We exposed an extract of complications in minimal invasive surgery for rectal cancer. The 
TaTME, as the newest procedure, had equal percentage of urethral injuries compared to LaTME 
and RoTME besides a low rate of anastomotic leakage. On the other hand, RoTME presented 
a lower percentage of bleeding and 30-days mortality in compare to especially TaTME. Further 
research is required, ideally randomized studies, to compare the three procedures regarding 
rates of serious intra and postoperative complications besides comparing their pathological 
results. Also, focus on which procedure who best treats a specific tumor stage, location and 
type of patient could possibly reduce complications and postoperative mortality in the future. 
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Figure 1: Flow diagram of article selection 
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Author Study design Pub. year Procedure 
No. of 
patients 
Bleed 
aEBL 
(ml) 
Trans Leak Urin Blad UTI W inf Bowel I abs P abs 30-d 
Lujan et al (11) Prospective 2013 LaTME 1387 14     81     36 92   85   16 
                                  
Penninckx et al (26) Retrospective 2013 LaTME 764       44ª               11 
                                  
Van der Pas et al (10) Randomized 2013 LaTME 699 22     58*   9   28 6 51   8 
                                  
Penna et al (23) Retrospective 2016 TaTME 634       35   7       15   17ªª 
                                  
Cho et al (12) Retrospective  2015 RoTME 278 3 179   32 5     2 1 3 1 0 
      LaTME 278 1 147   31 11     1 0 4   1 
Yamamoto et al (38) Prospective 2013 LaTME 490 3 28 8 40 5   11 36   3   0 
                                  
Fujii et al (39) Prospective 2012 LaTME 400 2 20 1 33 4   8         0 
      LaTME 77 2 100 3 7 1   3         0 
Hellan et al (16) Retrospective 2015 RoTME 425 3 119 5 37 30 5   16 7     1 
                                  
Kang et al (48) Prospective  2011 RoTME 389 3   8 27       2     12 0 
                                  
Fleshman et al (29) Randomized 2015 LaTME 240 8 256   5   2           2 
                                  
Park et al (34) Prospective  2015 RoTME 133   78 1 6 2 1   2   0   0 
      LaTME 84   82 3 3 1 1   0   0   0 
Liang et al (9) Randomized 2011 LaTME 169     4 4     1 9   2   0 
                                  
Chen et al (12) Prospective 2015 TaTME 50 1 68   3 0 0 1       3   
      LaTME 100 2 88   4 3 1 1       4   
Ielpo et al (33) Retrospective  2014 RoTME 56   280   4       3   4   0 
      LaTME 87   240   3       5   6   0 
Lacy et al (24) Prospective 2015 TaTME 140 5   4 12 3     0         
                                  
Saklini et al (31) Prospective  2013 RoTME 74   180   4       1   0   0 
      LaTME 64   210   8       0   2   0 
D'Annibel et al (15) Retrospective 2013 RoTME 50       5               0 
      LaTME 50       7               0 
Kim et al (59) Prospective 2012 RoTME 100     3 2               0 
                                  
Schiphorst et al (30) Prospective  2014 LaTME 86   200 10 4 2   1 1   4   1 
                                  
Fernández-Hevia et al (37) Prospective 2015 TaTME 37 1     2 1               
      LaTME 37 0     4 4               
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Yoo et al (32) Prospective 2015 RoTME 44 2 240   5 4         1   0 
      LaTME 26 0 215   0 1         0   0 
Gong et al (13) Randomized 2012 LaTME 67   86   1   1   1         
                                  
Levic et al (17) Retrospective 2015 RoTME 56   50   6 1   0       0 0 
                                  
Tuech et al (46) Prospective 2015 TaTME 56     2 3 5             0 
                                  
Baik et al (28) Prospective  2011 LaTME 54 0 313   4     3 3   0 3 0 
                                  
Hu et al (8) Prospective 2014 LaTME 51 0 204 2 1 1   1 2     0 0 
                                  
Burke et al (42) Retrospective 2016 TaTME 50   150   3 2 1         4 0 
                                  
Perdawood, Khefagie (5) Prospective 2015 TaTME 25   50   2 4       0       
      LaTME 25   100   4 8       2       
Marks et al (36) Prospective 2016 TaTME 17   282               0   0 
      LaTME 17   397               1   0 
Serra-Aracil et al (45) Prospective 2016 TaTME 32   158 0 3               0 
                                  
Rouanet et al (40) Prospective 2013 TaTME 30     6 0   2           0 
                                  
Leong et al (52) Prospective  2011 RoTME 29 1   4 3 1           1 0 
                                  
Muratore et al (53) Retrospective 2015 TaTME 26       2 1             1 
                                  
Rasulov et al (43) Prospective 2015 TaTME 22   30     2 1   1       0 
                                  
Atallah et al (58) Retrospective 2014 TaTME 20   153   1**       2     4 0 
                                  
Kang et al (49) Prospective 2016 TaTME 20   50 2 1 2 1           0 
                                  
Lacy et al (51) Prospective 2013 TaTME 20   45                   0 
                                  
Wang et al (50) Retrospective 2013 TaTME 16 0     0               0 
                                  
Fernandez et al (44) Retrospective 2013 RoTME 13   157   1 5             0 
                                  
Data systematically presented starting with the study counting the largest total number of patients  
                
Bleed: Bleeding 
 
aEBL: avarage Estimated Blood Loss  
 
Trans: Bloodtransfusion 
 
Leak: Anastomose leak   
Urin: Urine retention & complication Blad: Bladder & urinary injury 
  
UTI: Urinary tract infection  
 
W inf: Wound infection   
Bow: Bowel injury 
 
I abs: Intraabdominal abscess 
  
P abs: Pelvic abscess 
  
30: 30-days mortality   
*58 out of 461 patients             **1 out of 15 patients      ª44 out of 524 patients       ªª 17 out of 548 patients   
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Complication   Ta-TME     R-TME     L-TME   
  cases total percent cases patients percent cases patients percent 
Bleeding 7 243 2,9% 12 1136 1,1% 54 3839 1,4% 
EBL average  - 256 107,9 ml - 1079 143,7 ml - 2146 115,1 ml 
Need for blood transfusion 14 278 5,0% 21 1076 2,0% 31 1357 2,3% 
Anastomotic leakage 67 1151 5,8% 132 1647 8,0% 346 4982 6,9% 
Urine retention & complication 20 426 4,7% 48 978 4,9% 41 1654 2,5% 
Bladder and urethral injury 12 806 1,5% 6 558 1,1% 14 1241 1,1% 
Urinary tract infection 1 50 2,0% 0 56 0,0% 65 2814 2,3% 
Wound infection 3 182 1,6% 26 1355 1,9% 178 3516 5,1% 
Bowel Injury 0 25 0,0% 8 703 1,1% 8 1002 0,8% 
Intraabdominal abscess 15 651 2,3% 8 585 1,4% 158 3642 4,3% 
Pelvic abscess 11 120 9,2% 14 752 1,9% 7 223 3,1% 
30-days mortality 18 857 2,1% 1 1414 0,1% 39 5044 0,8% 
cases: the number of patients reported with the complication         
total: the number of patients reported with or without the complication       
percent: the percent of cases among the total number of patients       
EBL average in mililiter blood (not percent)             
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